Natasha Flowers
Overview
Explore the profile of Natasha Flowers including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
6
Citations
34
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Pennap D, Mosholder A, Ajao A, Boley E, Dharmarajan S, Akhtar S, et al.
Urology
. 2024 Jun;
192:111-118.
PMID: 38880345
Objective: To compare the risk of intentional self-harm (ISH) and suicide in older men using 5-α reductase inhibitors (5-ARIs) and alpha-blockers for benign prostatic hyperplasia (BPH). Observational research of older...
2.
Kozlowski S, Tworkoski E, Dharmarajan S, Flowers N, Kwist A, Shangguan S, et al.
Pharmacoepidemiol Drug Saf
. 2024 Feb;
33(2):e5749.
PMID: 38362655
Purpose: Pharmacy chains can differ with respect to the characteristics of their patient populations as well as their nonprescription products, services, and practices, and thus may serve as a surrogate...
3.
Kozlowski S, Flowers N, Kwist A, Dutcher S, Wernecke M, Kelman J, et al.
J Gen Intern Med
. 2022 Jun;
37(16):4292-4294.
PMID: 35650468
No abstract available.
4.
Kozlowski S, Flowers N, Birger N, Wernecke M, MaCurdy T, Kelman J, et al.
J Gen Intern Med
. 2020 Jun;
36(7):2170-2173.
PMID: 32578017
No abstract available.
5.
Bird S, Tian F, Flowers N, Przepiorka D, Wang R, Jung T, et al.
JAMA Oncol
. 2019 Dec;
6(2):248-254.
PMID: 31855259
Importance: Idelalisib (IDEL) is approved as monotherapy in relapsed follicular lymphoma (FL) and with rituximab (IDEL+R) for relapsed chronic lymphocytic leukemia (CLL). Toxic effects can be severe and treatment-limiting. Outcomes...
6.
Bird S, Flowers N, Zhao Y, McKean S, Izem R, Wernecke M, et al.
Clin Pharmacol Ther
. 2019 May;
106(5):1037-1045.
PMID: 31062343
Warfarin was selected as a case study to examine confounding when comparing a product across different manufacturers because it is a narrow therapeutic index drug with prevalent beliefs for brand-name...